Dear Editor, the recent article "Delirium and sleep disturbances in COVID-19: a possible role for melatonin in hospitalized patients?" is quite noteworthy \[[@bib1]\]. Zambrelli et al., mentioned that "*Melatonin\'s safety in doses up to* *10 mg* has *been shown to be very high in ICU patients and should be used in the prevention and treatment of sleep disturbances and delirium in COVID--19."* \[[@bib1]\]. The effect of melatonin on novel coronavirus (COVID-19) infection is a significant issue. In brief, melatonin is effective for reducing anxiety and useful for controlling insomnia. Some recent reports mention the benefit of melatonin in management of COVID-19 \[[@bib2],[@bib3]\]. Melatonin can help decrease lung fibrosis, which is a significant complication of COVID-19 \[[@bib2],[@bib3]\]. Therefore, it is recommended that melatonin should be used in any COVID-19 cases regardless of delirium or sleep disturbance.
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